Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

  • Technology appraisal guidance
  • TA260
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence:

  • Royle P, Cummins E, Walker C et al, Evidence review group report: Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine, December 2011

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Allergan

Professional or specialist, and patient or carer groups:

  • Migraine Action

  • Migraine Trust

  • Association of British Neurologists

  • British Association for Study of Headache

  • British Pain Society

  • Institute of Neurology

  • Migraine in Primary Care Advisors

  • Primary Care Neurology Society

  • Royal College of Anaesthetists

  • Royal College of Nursing

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

Other consultees:

  • Department of Health

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety – Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare Products Regulatory Agency

  • National Hospital for Neurology and Neurosurgery

  • Warwick Evidence

  • National Institute for Health Research Health Technology Assessment Centre

  • National Clinical Guidelines Centre

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on botulinum toxin type A by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Fayyaz Ahmed, Consultant Neurologist, nominated by British Association for the Study of Headache – clinical specialist

  • Dr Paul Shanahan, Consultant Neurologist, nominated by the National Hospital for Neurology and Neurosurgery – clinical specialist

  • Elaine Ransome, nominated by the Migraine Trust – patient expert

  • Wendy Thomas, Chief Executive of Migraine Trust, nominated by the Migraine Trust – patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Allergan

ISBN: 978-1-4731-6716-2